Ποια είναι η τιμή για Fresh Tracks Therapeutics, Inc. (FRTX)

Η τιμή για Fresh Tracks Therapeutics, Inc. (FRTX) είναι $0.94

Ποια είναι η κεφαλαιοποίηση αγοράς για Fresh Tracks Therapeutics, Inc. (FRTX)

Η κεφαλαιοποίηση αγοράς για Fresh Tracks Therapeutics, Inc. (FRTX) είναι $2.73M

Fresh Tracks Therapeutics, Inc. (FRTX) Τιμή και Κεφαλαιοποίηση Αγοράς

Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully completed Phase III clinical trials for the management of primary axillary hyperhidrosis. The company is also advancing BBI-02, an oral DYRK1A inhibitor targeting autoimmune and inflammatory diseases, and BBI-10, a covalent STING pathway inhibitor with potential for treating autoinflammatory and rare genetic disorders. Furthermore, Fresh Tracks is engaged in developing next-generation kinase inhibitors. The company maintains crucial licensing and collaborative partnerships, including agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. (and Dr. Nicholas S. Bodor), and AnGes, Inc. Founded in 2009 and based in Boulder, Colorado, the organization rebranded in September 2022, previously operating under the name Brickell Biotech, Inc.

Η τιμή για FRTX	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$1,876,002 $2.73M	NVDA	$5.452T	+199,574,612.63%
$1,545,028 $2.73M	AAPL	$4.490T	+164,364,578.08%
$1,432,295 $2.73M	GOOG	$4.162T	+152,371,752.22%
$1,265,039 $2.73M	MSFT	$3.676T	+134,578,547.49%
$974,858 $2.73M	AMZN	$2.833T	+103,708,151.11%

Η τιμή για FRTX

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$1,876,002 $2.73M